MedTrace Logo

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

NCT01130909 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-10-13

No results posted yet for this study

Summary

This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.

Conditions

  • Healthy

Interventions

DRUG

AZD6765

75 mg

DRUG

AZD6765

150 mg

DRUG

Ketamine

0.5 mg/kg

DRUG

Placebo

125 mL sterile NaCl 0.9%

Sponsors & Collaborators

Principal Investigators

  • Albena Patroneva, MD · AstraZeneca

  • Francine Santoro · Forenap

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130909 on ClinicalTrials.gov